Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Elevate Your Investing Strategy:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
The Straits Times Index Has Cracked the 4,200 Level: Is There Room for Further Gains?
The Straits Times Index (SGX: ^STI) posted a sterling performance year-to-date (YTD) as it broke multiple record highs. Earlier this month, the bellwether blue-chip index crossed the 4,000-mark for the first time as it recovered from April's tariff announcement. Just this week, the index has shot past the 4,200 level and shows no sign of stopping. Can this rally sustain, or should investors stay cautious for now? We unpack these developments to bring you some insights. A broad-based rally The surge in the STI is impressive, but investors may be surprised to note that the three local banks are not responsible for the bulk of this rise. DBS Group (SGX: D05), which occupies the largest weight within the STI at 25.1%, saw its share price increase by a little under 10% YTD. *Note: All weights are as of 31 March 2025. The next largest index component, OCBC Ltd (SGX: O39), takes up 16.3% of the index while Singapore's third largest bank, United Overseas Bank (SGX: U11) or UOB, had a weight of 12.4%. OCBC's share price increased just 3.4% YTD while UOB's shares inched up 1.9% YTD. Hence, it's clear that the banks have not contributed much to the index's stellar performance. So, the question is – which stocks did the heavy lifting this time? One example is Singapore Technologies Engineering (SGX: S63). The engineering firm's shares soared 77.9% YTD to hit S$8.27. Several other blue-chip stocks also posted strong share price gains. Property developers did well, with UOL Group (SGX: U14) surging 34.9% YTD and Hongkong Land (SGX: H78) soaring 42.9%. Sembcorp Industries (SGX: U96) leapt 41.8% YTD while Singapore Exchange (SGX: S68) saw its shares increase by 26.2% YTD. Local telco Singtel (SGX: Z74) also posted a strong performance with its share price jumping 33.7% YTD. Awaiting the banks' results These performances were achieved even when there were no major corporate announcements or earnings results. This suggests that the optimism could be related to the recent announcement of a large, S$1.1 billion capital injection by the Monetary Authority of Singapore to revitalise Singapore's stock market. There could be room for the rally to continue if the banks do report robust results. OCBC will report on 1 August while both DBS and UOB will announce their first half and second quarter earnings on 7 August. With interest rates set to hover 'higher for longer', the lenders could enjoy an unexpected tailwind if they can maintain their net interest margins. Fee income should also stay strong with wealth inflows into the region along with buoyant credit card spending. As for the rest of the STI's components, investors will also be keeping a close eye on their business updates and earnings announcements as the earnings season gets underway. Strategic reviews to unlock further value A catalyst that could take share prices higher is strategic reviews and long-term plans announced by several blue-chip players. Some companies also communicated their long-term objectives via Investor Day sessions that give investors a clearer idea of what to expect. For instance, ST Engineering released its Investor Day 2025 slides earlier this year and came up with another set of ambitious targets for 2029. The engineering giant also announced a progressive dividend policy that will add an incremental dividend based on one-third of the year-on-year increase in net profit from 2027 onwards. Hongkong Land also announced its strategic review late last year and has followed through with it by posting a higher year-on-year dividend for its 2024 results. Sembcorp Industries went a step further. The utility and urban development group not only announced its 2028 targets during its Investor Day 2023, but also announced a corporate reorganisation earlier this year. These developments injected a much-needed dose of optimism as investors witness clear progress towards attaining these goals. Singtel also reported a higher year-on-year dividend for fiscal 2025 and announced a S$2 billion share buyback programme to unlock more value for shareholders. Investors will be closely scrutinising the upcoming earnings season to determine if these companies can continue to report higher profits, free cash flow, and dividends. Get Smart: Monitor the business closely If you are afraid of a pullback in the STI, you are not alone. Some investors have expressed doubts about whether this surge is sustainable. One piece of good advice is to monitor the business behind the stock. If the business does well, the share price should naturally follow. Singapore's stock market is on a historic run, but can it last? We'll explore where interest rates are heading, whether blue-chip earnings can keep growing and more. Get the clarity you need — sign up now for our free webinar. When the market is unpredictable, where can you park your money with confidence? Our latest FREE report reveals 5 Singapore dividend-payers built to withstand global storms. Get it now and see what's still worth holding. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Royston Yang owns shares of DBS Group and Singapore Exchange. The post The Straits Times Index Has Cracked the 4,200 Level: Is There Room for Further Gains? appeared first on The Smart Investor. Sign in to access your portfolio
Business Insider
14 hours ago
- Business Insider
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences (ASMB) announced Phase 1a clinical and preclinical data for its herpes simplex virus, HSV, helicase-primase inhibitor candidates ABI-5366 and ABI-1179 are featured in multiple poster presentations, including one late-breaker, during the STI & HIV 2025 World Congress, taking place July 26-30, 2025, in Montreal, Canada, as well as in oral and poster presentations at the 49th Annual International Herpesvirus Workshop, taking place July 26-30, 2025, in Berlin, Germany. At the STI & HIV 2025 World Congress, two posters highlight the safety and pharmacokinetic profiles of ABI-5366 and ABI-1179 as observed in healthy participants in Phase 1a studies, supporting their progression to Phase 1b evaluation. The late-breaking poster for ABI-1179, the first scientific presentation of Phase 1a clinical data for this candidate, includes additional new interim data showing that, as was also the case in the ABI-5366 Phase 1a study, no clinically significant food effect was observed. Unblinded safety data for ABI-1179 are also included in this presentation. Elevate Your Investing Strategy:
Yahoo
2 days ago
- Yahoo
Assembly Bio's (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial
Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company announced positive topline results from its Phase 1b trial of ABI-4334, a capsid assembly modulator for the treatment of chronic hepatitis B. A scientist in a white lab coat working at a bench with biopharmaceutical equipment. The 28-day study showed HBV DNA reductions of 2.9 log10 IU/mL at 150 mg and 3.2 log10 IU/mL at 400 mg, with additional declines in HBV RNA. The lower dose achieved saturated inhibition of viral replication, while the higher dose may enhance suppression of cccDNA formation, a key viral reservoir. The drug was well-tolerated, with no serious adverse events and pharmacokinetics supporting once-daily oral dosing. These results activate a licensing decision for Gilead Sciences, which holds rights to further develop ABI-4334. Assembly Biosciences, Inc. (NASDAQ:ASMB) is a clinical-stage biotech focused on small-molecule therapies for serious viral infections. Its pipeline includes candidates for hepatitis B, hepatitis delta, herpesviruses, and transplant-related infections. The company collaborates with Gilead Sciences to advance next-generation antiviral treatments. While we acknowledge the potential of ASMB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
